Treatment of Benign Prostatic Hyperplasia (BPH)
Introduction to Tadalafil
- The American Urological Association (AUA) guidelines provide a moderate recommendation (Evidence Level: Grade B) supporting the use of 5 mg daily tadalafil for patients with lower urinary tract symptoms (LUTS) associated with BPH, regardless of whether they have concurrent erectile dysfunction (ED) 1
Dosing and Administration
- The recommended dose of tadalafil for the treatment of Benign Prostatic Hyperplasia (BPH) is 5 mg once daily, taken at approximately the same time each day 1
- Tadalafil should not be combined with alpha-blockers for LUTS/BPH as this combination offers no advantages in symptom improvement over either agent alone and may increase side effect risk 1
Special Considerations
- For patients with moderate renal impairment (CrCl 30-50 mL/min): Start with 2.5 mg daily; may increase to 5 mg based on individual response, however this information is not supported by a valid citation
- For patients with severe renal impairment (CrCl <30 mL/min) or hemodialysis: Not recommended for once-daily use, however this information is not supported by a valid citation
- For patients with mild to moderate hepatic impairment (Child-Pugh Class A or B): Use with caution, however this information is not supported by a valid citation
- For patients with severe hepatic impairment (Child-Pugh Class C): Not recommended, however this information is not supported by a valid citation